Latest news

Thumbnail image for Pfizer pulls plug on Inlyta trial

Pfizer pulls plug on Inlyta trial

Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.

12th April 2018

Thumbnail image for Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.

11th April 2018

Thumbnail image for vTv reports Alzheimer’s candidate failure

vTv reports Alzheimer’s candidate failure

It is looking likely that another late-stage candidate for Alzheimer’s disease will fail to make it past Phase III trials, with vTv Therapeutics’ experimental therapy the latest in a long line to miss its targets.

11th April 2018

Thumbnail image for NICE no for Roche’s Alecensa

NICE no for Roche’s Alecensa

The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer.

11th April 2018

Thumbnail image for EU regulators expand reach of Sobi’s Kineret

EU regulators expand reach of Sobi’s Kineret

European regulators have expanded the scope of Sobi’s Kineret to include the treatment of Still’s disease, a rare, systemic, multi-organ, auto-inflammatory disorder that affects around 25,000 children and adults in the EU.

11th April 2018

Thumbnail image for AZ buys Ionis’ NASH candidate

AZ buys Ionis’ NASH candidate

AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million

10th April 2018

Thumbnail image for MSD’s Keytruda bags another trial success in NSCLC

MSD’s Keytruda bags another trial success in NSCLC

MSD’s Keytruda has significantly increased overall survival in patients with lung cancer expressing any level of PD-L1 when used as monotherapy in the first-line setting, potentially significantly increasing the drug’s treatment scope.

10th April 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download